[ADMA] ADMA Biologics Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.5 Change: -0.1 (-2.17%)
Ext. hours: Change: 0 (0%)

chart ADMA

Refresh chart

Strongest Trends Summary For ADMA

ADMA is in the long-term down -58% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.7 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0.2% Sales Growth - Q/Q0.94% P/E-1.79
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-42.78% ROE-108.07% ROI-50.92%
Current Ratio8.18 Quick Ratio7.67 Long Term Debt/Equity0.55 Debt Ratio0.28
Gross Margin37.25% Operating Margin-231.07% Net Profit Margin-247.78% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities10.46 M Cash From Investing Activities-6.87 M Cash From Operating Activities-4.22 M Gross Profit590 K
Net Profit-3.61 M Operating Profit-3.2 M Total Assets33.93 M Total Current Assets30.98 M
Total Current Liabilities3.79 M Total Debt15.09 M Total Liabilities20.5 M Total Revenue1.5 M
Technical Data
High 52 week5.44 Low 52 week2.06 Last close5.44 Last change0.37%
RSI64.6 Average true range0.32 Beta0.52 Volume94.85 K
Simple moving average 20 days8.6% Simple moving average 50 days10.55% Simple moving average 200 days49.85%
Performance Data
Performance Week9.02% Performance Month12.86% Performance Quart39.85% Performance Half77.78%
Performance Year41.3% Performance Year-to-date69.47% Volatility daily2.91% Volatility weekly6.5%
Volatility monthly13.33% Volatility yearly46.17% Relative Volume814.37% Average Volume124.83 K
New High New Low

News

2019-09-09 14:54:50 | What Kind Of Investor Owns Most Of ADMA Biologics, Inc. NASDAQ:ADMA?

2019-08-22 07:48:00 | ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

2019-08-08 07:51:08 | Breakeven On The Horizon For ADMA Biologics, Inc. NASDAQ:ADMA

2019-08-08 07:08:00 | ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results

2019-07-08 08:22:05 | ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®

2019-06-27 09:30:13 | Did ADMA Biologics, Inc. NASDAQ:ADMA Insiders Buy Up More Shares?

2019-06-27 09:28:19 | How Many ADMA Biologics, Inc. NASDAQ:ADMA Shares Did Insiders Buy, In The Last Year?

2019-06-18 16:35:33 | ADMA Biologics: Selloff Creates Buying Opportunity

2019-06-06 07:25:00 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ADMA Biologics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

2019-05-30 18:14:45 | ADMA Biologics Is De-Risked and Ready to Rise

2019-05-29 07:11:00 | ADMA Biologics to Present at Upcoming Investor Conferences

2019-05-24 10:30:00 | These 3 Biotech Stocks Are Attracting Insider Buying

2019-05-21 16:20:00 | ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2019-05-21 09:15:02 | Adma Biologics Inc ADMA President and CEO Adam S Grossman Bought $120,000 of Shares

2019-05-16 08:00:00 | NeuBase Therapeutics Designates Industry Leaders to Board of Directors 

2019-05-15 16:35:36 | ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock

2019-05-10 06:58:00 | FDA Approves Prior Approval Supplement for BIVIGAM®

2019-05-08 19:03:16 | Adma Biologics: 1Q Earnings Snapshot

2019-05-08 16:18:00 | ADMA Biologics Reports First Quarter 2019 Financial Results

2019-04-17 07:08:00 | ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections

2019-04-03 17:00:19 | ADMA Biologics: Wall Street Projects Robust Revenue Growth

2019-04-03 15:27:13 | Why ADMA Biologics Stock Soared Yesterday

2019-04-03 08:19:01 | The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

2019-04-02 18:58:00 | ADMA Receives Department of Health and Human Services U.S. License

2019-04-02 10:26:35 | ADMA Biologics Rips Higher On FDA Nod For Immunodeficiency Therapy

2019-04-02 09:00:00 | ADMA Biologics' stock rockets on heavy volume after FDA approval of immunodeficiency treatment

2019-04-02 07:30:37 | The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

2019-04-01 20:09:30 | FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin

2019-03-13 20:19:44 | Adma Biologics: 4Q Earnings Snapshot

2019-03-13 17:05:00 | ADMA Biologics Reports Full Year 2018 Financial Results

2019-02-25 07:38:00 | ADMA Biologics to Present at Upcoming Investor Conferences

2019-02-12 12:30:00 | Watch These Tech Stocks Set The Pace On Tuesday 2/12/19

2019-02-12 07:38:00 | ADMA Biologics Enters Into $72.5 Million Loan Facility with Perceptive Advisors

2019-01-07 07:08:00 | ADMA Biologics Submits Response and Provides Supplemental Information to FDA for BIVIGAM® Complete Response Letter

2018-12-26 11:40:35 | Have Insiders Been Buying ADMA Biologics, Inc. NASDAQ:ADMA Shares This Year?

2018-12-23 07:25:54 | Here is What Hedge Funds Think About ADMA Biologics Inc ADMA

2018-12-20 18:20:00 | Here's Why ADMA Biologics Is Getting Hammered Today

2018-12-20 06:08:00 | ADMA to Host Conference Call to Discuss Recent Regulatory Update on BIVIGAM® PAS Submissions

2018-12-19 18:36:23 | FDA declines to approve re-launch of ADMA Biologics' Bivigam

2018-12-19 17:58:00 | ADMA Biologics Provides Regulatory Update on BIVIGAM® PAS Submissions

2018-12-19 09:18:47 | ADMA Biologics Provides Regulatory Update for BIVIGAM®

2018-12-17 06:30:00 | ADMA Biologics Upcoming PDUFA Dates and Milestones

2018-12-16 14:18:20 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

2018-11-13 08:10:00 | Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies — Future Expectations, Projections Moving into 2018

2018-11-08 17:27:23 | Adma Biologics: 3Q Earnings Snapshot

2018-11-08 17:05:00 | ADMA Biologics Reports Third Quarter 2018 Financial Results

2018-10-30 10:00:00 | ADMA: Bivigam Delay But Will Recoup Sales Later

2018-10-17 07:08:00 | ADMA Biologics Receives PDUFA Date for RI-002

2018-10-11 08:48:00 | ADMA Biologics Provides Regulatory Update for BIVIGAM®

2018-10-03 07:08:00 | ADMA BioCenters Receives FDA Approval for Third Plasma Collection Center